Serum Leucine-Rich α2 Glycoprotein: A Novel Biomarker For Small Bowel Mucosal Activity in Crohn’s Disease
Active lesions in the small bowel (SB) have been independently associated with poorer prognoses in patients with Crohn’s disease (CD)1; however, there has been a lack of accurate and convenient screening methods. Past studies have found that serum levels of the glycoprotein leucine-rich α2 glycoprot...
Gespeichert in:
| Veröffentlicht in: | Clinical gastroenterology and hepatology 2022-05, Vol.20 (5), p.e1196-e1200 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | Active lesions in the small bowel (SB) have been independently associated with poorer prognoses in patients with Crohn’s disease (CD)1; however, there has been a lack of accurate and convenient screening methods. Past studies have found that serum levels of the glycoprotein leucine-rich α2 glycoprotein (LRG) correlates with endoscopic activity in ulcerative colitis,2,3 and this is now available for routine clinical use as a biomarker in patients with inflammatory bowel disease in Japan. LRG has not yet been thoroughly verified in CD, and we investigated whether it can be used as a serum biomarker for detecting SB mucosal activity in patients with CD. |
|---|---|
| ISSN: | 1542-3565 1542-7714 |
| DOI: | 10.1016/j.cgh.2021.06.036 |